Inside Singapore’s COVID-19 Vaccine Development: Lunar-Cov19
A Singapore-based team at Duke-NUS Medical School have spent the last year working on a COVID-19 vaccine. How close are they to producing one and will it help end the pandemic?
Duke-NUS Medical School in Singapore and San Diego-based Arcturus Therapeutics have partnered to develop a COVID-19 vaccine. It is a self-replicating mRNA vaccine. So while the mRNA technology is similar to vaccines from Pfizer-BioNTech and Moderna, this vaccine requires a lower dose.
From pre-clinical trial to animal testing and finally to human trials, follow the whole process of vaccine development to see how COVID-19 vaccines are being produced at record speeds. Meet the scientists on the frontlines of the war against the deadly coronavirus that has claimed millions of lives around the world.
The COVID-19 Vaccine Race: From Trials To Transport, What Does It Take?
Human trials have started in Singapore and the Duke-NUS team is one step closer to producing a viable COVID-19 vaccine. However other researchers in other parts of the world are ahead in the race.
As the world waits with bated breath for a possible end to the pandemic, is a viable COVID-19 vaccine the answer? But creating a viable vaccine is just the first step; producing enough for everyone is a different mountain to climb. As Pfizer-BioNTech, Moderna and other first-generation vaccines become available, what happens to the ones that are a step behind?
Meanwhile, vaccine hesitancy and an ever-growing anti-vaccine movement could threaten to derail our path towards herd immunity through vaccination. Could this lead to prolonging the coronavirus pandemic?